OriGene Technologies, Inc.
OriGene
Y
Te
ou
chnolo
min S
g
h
ies,
u, P
In
hD
c.
.
Director of
Y
Gene
oumin
Expre
Shu,
s
P
si
h
on
D.
Director of Gene
888.26
Expre
7.443
ssion
6
Application Note ww
888.26
w.orige
7.443
ne.co
6
m

Application Note www.origene.com
The TissueScan Advantage:
The TissueScan Advantage:
Unlike microarrays that explore expression changes of multiple genes in a single tissue, TissueScan reveals the
expre
Unlike
ssi
micro
on chang
arrays
es
that
of a
explore
single ge
exp
ne
re
in
ssi
multiple
on chang
tissu
es o
e
f
s
mu
by
ltiple
a simpl
gen
e
es
qPCR
in a
exp
single
eriment.
tissue,
Therefore
TissueScan
Tissue
reveal
Scan
s the
c
expre
an be
ssi
c
on
ons
chang
idered
es
as
of
a
a
“R
single
evers
ge
e-m
ne
ic
in
roarray”.
multiple
It
tissu
is espe
es by
cially
a simpl
usef
e
ul
qPCR
for validation
experiment.
of the
Therefore
large numbe
Tissue
r of
Scan
leads
from
can b
a
e
microa
consid
rray
ered
date.
as a “Rev
| Biomarker
erse-microarray”.
V
It
alida
is espe
tion
cially useful for validation of the large number of leads
from a microarray date.
OriGene
� Convenient - Remove the hurdle Cancer Biomarkersof tissue procurement so you can focus on validation and discovery
� Comprehensive – 48-96 unique samples per panel covering normal and all progression stages
6 Taft Court
� Convenient - Remove the hurdle of tissue procurement so you can focus on validation and discovery
�
�
E
C
c
o
o
m
n
p
o
r
m
eh
ic
e
a
n
l
s
-
iv
Less
e – 4
than
8-96
$
u
5.00
niqu
per
e sa
sam
mple
ple
s p

er panel covering normal and all progression stages
Rockville, MD
�
�
R
Ec
e
o
lia
n
b
o
l
m
e
i
-
c
Pa
al -
thologi
Less
st
than
verified
$5.00
tissue
per sam
s wit
ple
h full

consent, detailed pathology reports and histology images
20850
�
�
Fast
Relia
-
b
R
le
e
-
su
Pa
lts
thologi
in les
st
s t
verified
han 2 ho
OriG
tissue
urs
ene
s wit
Te
h full
chnolo
consent
gies,
, detailed
Inc.
pathology reports and histology images
� Whole Product Solution - Source materialYos umavailablin She u, PhD.
1-888-267-4436
� Fast - Results in less than 2 hours
� Whole Product Solution - Source
Directo
mat
r of
erial
Gene
s availabl
Expre
e
ssion
www.origene.com/genee
Applica
xpr
tion
ession
example: 888.267.4436
Application Note
techsupport@origene
Applica
To illustrate
.com
tion example:
the validity of TissueScan, we used L
w
u
w
ng
w
C
.o
a
r
n
i
c
g
e
e
r
n
P
e
a
.
n
c
e
o
l
m
(HLRT-101) to evaluate the expression level of
Topoi
To illustrate
somera
the
se
validity
II alpha,
of
which
TissueS
has
can,
bee
w
n
e
kno
us
w
ed
n
L
to
un
b
g
e
C
upre
anc
gulate
er Pan
d
e
in
l (
a
HL
large
RT-1
pe
01
rcenta
) to ev
ge
alu
of
ate
lu
t
ng
he
ca
ex
ncers
(1-2)
pression
.
le
A
ve
pair
l of
of primers was designed to detect the transcript OriGene of Tethis chnologene gies, (NCBInc. I accession #NM_001067). SYBR Green I based
TissueScan Oncology Panel:
TissueScan qPCR Array:

Topoisomerase II alpha, which has been known to be upregulated in a large percentage of lung cancers
(1-2)
. A pair
real
of p
-time
rimers
PCR
was
wa
de
s
si
pe
gn
rformed
ed to detect
in a
the
Perkin
transcript
Elmer
of
theYo
this
rumal mi
gene
ncy Shcler u
(NCB
, P(model hD
I
.
a

cc
#PE77
ession
00).
#NM
The
_00
raw
1067
data
). SY
(Fig
BR
ure
Gre
1A)
en I
and
bas
the
ed
Biomarker validation via gene expression profiling in a large
expre
real
n
-time
umb
ssion
er
PCR
le
of
vel
wa
tumors
plot
s pe
calcul
rformed
ated
in
by
a Perkin
the Ct Diremethod
Elmer
ctor of
the
(FigGene
rmal
ure Expre
cy
1B)
cler
as
(model
rsie on shown
#PE77
below
00).
. A
The
seco
raw
nd
data
panel
(Fig
in the
ure
kit
1A)
was
and
us
the
ed
Gene Expression Profi les in Cancer Prog
with
expre
ression in
beta-acti
ssion level
n control
plot
T
calcul
w
prim
o Hours
ated
ers p
by
rovid
the
ed
Ct
in
method
the kit (Figu
(Fig
888.26
ure
re 1C).
1B)
7.443
are shown
6
below. A second panel in the kit was used
_____________A__p__p_l_ic__a_t_i_o_n__ N__o__te________________
with
___
beta-acti
______
n
_
control
_____
prim
___
ers
___
p
_
rovid
___
ed
__
in
_

_
the
__
kit
__
(Figu
_w_w__w
re
_.o_
1C).
ri_g_e_ne_._co m
Introduction
Abstract:
The TissueScan Advantage:
TissueScan is a unique qPCR array of fi rst-strand cDNA from
hundreds
TissueS
of
can
clinical
is a
tumor
uniq
Unli
ue
samples.ke
qP
micro
CR
a
a
rrayIt
rray
provides s that
of first-strand
explore a fast expand r
cDNA
ession ch
from
anges
hun
of
dred
multiple
s of
gen
clini
es
cal
in a
tumor
single
sam
tissu
p
e,
les.
Tissue
It provides
Scan reveal
a
s
fa
the
st
accura
and
te
a
gene
ccurate
expression
expre
gene exp
profi
re
ling
ssion
ssion
across
changes
profilin
a
of
g
large
a single
acro
number
gene
ss a large
of
in multiple tissues by a simple qPCR experiment. Therefore TissueScan
number of cancer patient samples. High-quality cDNAs were
cancer
prep
pa
ared
tient samples.
from highly-do
High-quality
can be con
cumented
cDNAs
sidered
can
were
as a “
cer
prepared
Reverse-
biopsy
from
microarray”. It is especially useful for validation of the large number of leads
from a microarray date.
samples, normalized and assembled into ready-to-use gene
highly-documented
expression panel
cancer
s. This
biopsy
alleviates
samples,
for

rese
normalized
archers
and
the tedious work of large sample collection and the meticulous
assembled
work o
into
f R
read
NA/
y-to-use
cDNA �p
gene
rConvepa
expression
renientation, - wRemove h
panels.
ile fac
This
the ilitahurdl
allevia
ting e q
tes
uof ictissue k andpro reliablcuremeent profiling so you of can gfocuene s expression validation on levels and discovery across cancer
for researchers
progression
the
stages.
tedious
�
work
TissuComp
of
eScan re
large
hensicom
sample
ve – bi48nes -
collection
96 uthe niquhiegh
and
samsenples itpivity and specificity of the RT-PCR methodology with a
the meticulous
well-design
work
ed multi-sam
of RNA/cDNA
ple
prepara
format.
tion,
It

is
while
an excell
facilita
ent
ting
1A.
er p
Real-time
anel cove

r
PCR
ing no
re
rm
sult
al
s
a
with
nd a
Topo
ll prog
II
re
p
s
r
s
imers.
ion sta

ge
1B.
s
Normalized relative expression of Topo II alpha among 48
� Economical - Less than $5.00 per sam
tool
ple
for
A.
validat
Real-time
ion
PCR
of
re
potenti
sults with
al
To
can
po II
c
pr
e
im
r
e
markers
rs
such
lun
as
g sa
those
OriG
mpl
ene
es
Te

chnologies, Inc.
quick and reliable profi ling of � gene Reliaexpression ble - Pathologilevels st verified across cancer tissues with full
1A.
con
Real-time
sent, detailed
PCR re
pat
sult
hology
s with
re
Topo
ports
II
and
primers.
histolo

g
1B.
y images
Normali

zed Youmrelative in Shu, PexhD.pre ssion of Topo II alpha among 48
obtained by microarray or differential display. Director of Gene Expression
________________
�
_
Fast
____
-
_
R
_
e
_
s
_
u
_
lts
_
i
_
n
_
le
_
s
_
s
_
t
_
h
_
an
_

_
2
_
h
_
o
_
u
_
rs
_

lung samples
progression stages. TissueScan combines the high sensitivity and
___________________________________________________
888.267.4436
specifi city of the RT-PCR methodolog
� Whole Prod
y with
uct
a well-designed
Solution - Source
multi-
matAperialplics aavailabltion Ne ote www.origene.com
Who needs TissueScan?
sample Introducformat.tion It is : an excellent tool for validation of potential
cancer markers such as
Applica
those obtained
tion example:
by microarray or differential
Scientists in several the following research areas would benefit from TissueScan.
1. Scientists who have obtained the leads for potential biomarkers are generally derived from studies with a
display.
To illustrate the validity of TissueScan, we used L
relatively
ung C
sma
anc
ll
e
sample
r Pan
size
el (
.
H
To
LR
validate
T-101
su
)
ch
to
candi
eva
da
lu
te
a
gene
te th
s,
e
it
e
is
x
cru
pr
c
e
ial
ss
to
io
investigate
n level o
with
f
a larger
sample pool to gain statistic relevance.
The importance
Topoi
of
som
cancer
erase
bioma
II alpha,
rkers
which
is multifacet
has been kno
ed.
w
2.
n
With
to
Scientist
be
validated
upre
s with
gulate
biomarker bioma
d in
candid
a large
rakers, tes de
pe
rived
rcenta
we from can ca
ge
ncp
of
err ocell
lu
v
ng
ide line
ca
study clea
ncers
(1-2)
or r from an
.
imal
A pair
studies. It is pivotal
Application Example:answer to the
o
most
f prim
impo
ers wa
rta
s d
nt
es
questio
igned to
ns
detect
can
the
cer
transcript
research
of
to
e
profile
this
rs a
gene
nd
the gene
cli
(NCB
nicia
s in hum
I
ns
a
an
cc
ca
wish
e
ncer
ssio
tissue
n
to
#N
address,
s
M
for
_
it
0
s
0
si
1
gn
0
i
6
fic
su
7
a
)
n
.
c

ch
e
S
i
Y
n c
a
B
li
s
n
R
ic
,

a
G
what
l d
r
i
e
ag
e
n
n
o

s
I
i

s
b
a
a
n
s
d
e
th
d
e

rapy
3. Researchers validating cancer staging markers. One key feature of TissueScan is that each panel contains
To illustratype te the of cancevalidity r
real
of is Tit?
-time
issueScan, Whi
PCR
ch
wa
we stage
s
used
performed
is Lung it in?Cancer
in

a
What
Perkin
Panel mole
Elmer
cular
the
one
r
can
subtype
mal
cer
cy
type
cler
cross
is
(model
it?
all st

age
Can
#PE77
s, providi
it be
00).
ng a com
matche
The
preh
raw
ensive
d
data
to
la
a
nd
(Fig
spe
scape
ure
c
for
ific
exp
1A)
ressi
and
on survey.
the
expression level plot calculated by the Ct method 4. Re
1C.
(Fig
Re
ure
al-time
1B) ar
PCR
e shown
result
belo
s with
w. A
beta-acti
second
n
pa
prime
nel in
rs
the kit was used
(HLRT-101) therapto evaluaeutic te rethe giment?
with
expression
beta-acti
Is level
n
th
control
e canof Topoisomerase c
prim
er re
ers
sp
p
ondi
rovid
II nalpha,
ed
g
i
t
n
o
the
the
kit
tr
(Figu
e
B
sea
1C.
a
.
t
N
rche
m
or
Re
re
e
ma
s studying
al-time
n
1C).
t
li
?
ze

d
Is
re
PCR

l
SNP/chromo
i
a
t
ti
r
v
e
e
c
e
re
u
xp
sult
r
r
r
e
som
in
ss
s
g
io
a
with
?
n
l aberration
o

f TOPO
a
II al
ca
ph
ncer
a am
risk.
ong
As
4
the
8
48 samples are derived from 48
individual
lung sa
s,
m
they
ples
can be used studied for the frequen
beta-acti
cy for
n
particul
prime
ar
rs
SNP or chromosomal rearrangement.
which has been known to be upregulated in a large percentage of
Comp
In this
aring
experi
the can
m
ce
ent,
r with
the
the normal
topoisom
tissues
e
may
rase
reveal
II alpha
potential
ge
associ
ne wa
ation
s sh
of a
owed
genotype
to
with
expre
cancer
occurrence.
ss at very low levels in tissues of
lung cancers.Yet despite A pair of ofprimers the great was designed amount to of detect effort the in transcript this directio
5.
n,
Renorm
In
the
sea
this
rche
numbe
al/stag
experi
r who wise
m
r
0
h
ent,
of
to
(Sample
study
can
the
relevan
c
topoisom
e
1
r
-
bi
8).
ce
omarke
of
In
a
e
can
all
rase
cer
but
rs
bioma
II
one
in
alpha
rker
clinical
tissue
for
ge
its
ne
prevalen
(well
u
wa
se
s
10,
ce
i
sh
s
in
owed
tumor
other can
to
stage
c
expre
er type
IA),
s.
ss

at
the
very
expressio
low level
n levels
s in tissue
are markedly
s of
Many genes that have aberrant expression in one cancer type are also present in other types of cancer.
of this gene.quite SYBR small. Green Although I based real-time many candiPCR date was performed.biomarkers The have
highe
One
norm
been well-kno
a
r
l/stag
rep
than
wn oexampl
e
rted,
in
0
the
(Sample
normal
e very is BRCAfew 1,
1
ti
-
the
8).
ssue
have brea
In
s,
st
all
sup
canbe
but
po
ceen r su
one
rting
sceptibilitsufficie
tissue
the notio
y gene. n
(well
tly
n that
In addition
10,

tumor
topoiso
to brea
stage
mera
st canc
IA),
se can
er,
the
serve
expressio
as a
n
vali
levels
d bioma
are markedly
rker for lung
cancer. After primer design, the complete experiment took about 2 hours, with 20 minutes of hands-on time.
raw data validated (Figure A) to and justify the expression their use level in developiplot calculang ted druby gthe s oCt r makin
mutations highe
g patie
r in than t
nt
he BRCA
care
in the 1 ge
deci
normal ne also
sions.
incretissuease
One
the s, suprisk
of
opf oovarian,
the
rting
majo
the Fallopian notio
r
tubn e, thatprostate topoisoand comeralon cancersse can . serve as a valid biomarker for lung
Re
can
cently
cer
an
.
i
After
nternatio
primer
nal study
d
sho
esi
w
g
ed
n,
that
the
a
comple
newly disc
te
overed
experime
gene that
nt
elev
took
ates
abo
breast
ut
cancer
2 hours,
risk also
with 20 minutes of hands-on time.
method obsta(Figure cleB) s are in bshoiomarkewn at right.r validation A second is panel the in difficulty the kit was to acces
elevates
s suf
p
f
r
i
o
c
s
i
tate
en
can
t n
c
u
er
m
risk
ber of clinical samples with
used with beta-actin control primers provided in the kit (F
adequate documentation. Many of the prelimin
igure C).
ary Producreseart ofch fering: rest after obtaining data from cancer cell lines
Your Gene Company
or after microarray screening using a small number of
With
paired
Cytomy
can
x’s large
cer/n
hum
orm
an tissue
al
ban
tissue
k, OriGen
s.
e has been expanding our TissueScan line with monthly new
Your Gene Company
The results showed that TOPOII expression levels are markedly higher
releases. Besides the growing repertoire of panels that are focused on the cancer type of a particular tissue
origin, OriGene launched a brand-new TissueScan: the Cancer Survey Panel. Instead of focusing of a particular
than in TissueSthe normal can tissues,qPCR supporting arrays the are notion invented that topoisomerase to help researchers cancer type, to Canget cerea Survesy y accePanel isss a 96to -well this qPCR muplate chof -ne8X12e ded arrangement, containing 8 cancer types with
can serresouve as a valid biomarker for lung cancerrce so as
1A.
to
Real-time
build a ra
PCR
mp
re
to
sult
. a highe
s with
r
Topo
ground.
II primers.
Each
12 saCm

Ti
. pRle
1B.
ssueSca
esa flo-rt iemae chP tyCp
Normali
n
R e.
zed
panel
r eTshureltes owu
relative
i
t
s
i toh

f
co
btheet
ex
ntains
a-12a scatimn pple
pression
4
rsi
8
m a
of

ree
or
rsnormal
Topo
96
II
first-stra
controls that are surgical samples from the
cancer patients but defined by the pathologist as normal (or stage 0).
alpha am
nd
ong 48
cDNAs prepared from individual tumor tissue block. The r
l
e
un
s
Product Offering:
TissueSca
g
e

a
sa
rc
m
h
p
e
l
n
e
r
Cat#
s
c

an simply aliquot real-time PCR
master mix with gene-specific primer pair, load onto a PCR machine and walk aw
D
ay.
iseas

e
Two
focus
ho

urs later, the
CSRT101, CSRT501 Cancer Survey I (96 Tissues)
TissueScan
survey
kit
for
includes
the gene
two identical
expression
48-well
level
panels,
across
beta-actin
48 samples are
BC
availa
RT101, B
ble.
CRT50
The
1
who
Prost
l
a
e
te
pro
Canc
c
er
e
(4
ss
8 Ti
i
s
s
su

e
quick,
s)
control
sen
primers
sitive,
and
accurate
a copy of the
and
Applica
painless.
tion Guide.

The normalized
BCRT101, BCRT501 Breast Cancer I (48 Tissues)
BCRT102, BCRT502 Breast Cancer II (48 Tissues)
cDNAs are lyophilized in 48-well PCR plates.
HCRT101, HCRT501 Colon Cancer (48 Tissues)
BCRT102, BCRT502 Colon Cancer II (48 Tissues)
For
Protocol
more informa
at a glance:
tion, contact us at 1-888-267-4436,
LVRT101, LVRT501 Liver Cancer (48 Tissues)
HSRT101, HSRT501 Sarcoma (48 Tissues)
techsupport@origene.com, or visit www.origene.com.
HLRT101, HLRT501 Lung Cancer (48 Tissues)
Before using TissueScan: Design a pair of real-time PCR p
HO
rime
RT10
rs
1, HORT
spec
501
ific for
O
e
va
ach
rian C
g
an
ene
cer (48
of
Tis
i
s
ntere
ues)
st.
Step 1:
MERT101, MERT501 Melanoma (43 Tissues)
1C. Real-time PCR results with beta-actin primers
HTRT101, HTRT501 Thyroid Cancer (48 Tissues)
Prepare qPCR master mix with gene-specific primers and aliqu
EDRT1
o
01
t
,
into
EDRT5
the
01
PCR
Endometri
panel.
um (48 Tissues)
Step 2:
In this experiment, the topoisomerase II alpha gene waLYRT1s sh01, owed LYRT50to 1 expreLymphomss at very a Cancer low (48 levelTissues s)in tissues of
Perform thermal
norm
cyclin
al/stag
g
e
(see
0 (Sample
appendix
1-8).
for
In all
list
but
of
one
com
tissue
patib
(well
le
HKRT
the
10, 101,
rm
tumor HKRT50
al cyc
stage 1
lers)
IA),
.
Kidney

theCan expressiocer (48 Tissuen levels s) are markedly
higher than in the normal tissues, supporting the notio
HG
n
RT10
that
1,
topoiso
HGRT501
mera
G
se
ast
can
roesop
serve
hageal
as
(48 T
a
is
vali
sues
d
)
Step 3:
biomarker for lung
cancer. After primer design, the complete experimen
CCRT1
t took
01,
abo
CCRT
ut
501
2 hours,
Cro
with
hn's an
2
d
0
C
minutes
olitis (48 Tis
of
sue
hand
s)
s-on time.
Plot the expression profile of your gene of interest using Ct (threshold cycle) method.
Your Gene Company
Protocol Guide ı 2008 View entire protocol online at www.biotechniques.com/protocol ı BioT
Yo
echniques
ur Gene C
ı
o
11
mpany
Your Gene Company
Origene protocol.indd 11 10/25/07 6:48:44 PM
Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76